An Anacor Pharmaceuticals drug aimed at fungal infections of the skin and nails did well in an early clinical trial. The Palo Alto company tested the drug, AN2718, for 21 days to see if it irritated the skin. Early, or Phase I clinical trials typically test the safety and tolerability of drugs in small numbers of people. Later tests evaluate how well the drugs work, though some of that type of data can also be gleaned earlier.
